Recently, the FDA-approved drug belantamab mafodotin (GSK2857916), an ADC that targets B-cell maturation antigen (BCMA) in multiple myeloma cells using MMAF as a payload, induced ICD in BCMA-expressing cancer cells and promoted DC activation in vivo (Yu et al., 2020). The gene discussed is TNFRSF17; the disease is plasma cell myeloma.